Clinical Results of Drug-Coated Balloon Treatment in a Large-Scale Multicenter Korean Registry Study

• Published in: Korean circulation journal 2022, 52(6), , pp.444-454
• Main Authors: Lee, Sang Yeub, Cho, Yun-Kyeong, Kim, Sang-Wook, Hong, Young-Joon, Koo, Bon-Kwon, Bae, Jang-Whan, Lee, Seung-Hwan, Yang, Tae Hyun, Park, Hun Sik, Choi, Si Wan, Lim, Do-Sun, Kim, Soo-Joong, Jeong, Young Hoon, Lee, Hyun-Jong, Lee, Kwan Yong, Shin, Eun-Seok, Kim, Ung, Kim, Moo Hyun, Nam, Chang-Wook, Hur, Seung-Ho, Kim, Doo-Il
• Format: Article
• Language: English
• Subjects: Original Research; 내과학
• ISSN: 1738-5520; 1738-5555
• DOI: 10.4070/kcj.2021.0261

The aim of this study was to demonstrate the efficacy and safety of treatment with drug-coated balloon (DCB) in a large real-world population. Patients treated with DCBs were included in a multicenter observational registry that enrolled patients from 18 hospitals in Korea between January 2009 and December 2017. The primary outcome was target lesion failure (TLF) defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically indicated target lesion revascularization at 12 months. The study included 2,509 patients with 2,666 DCB-treated coronary artery lesions (1,688 [63.3%] with in-stent restenosis [ISR] lesions vs. 978 [36.7%] with de novo lesions). The mean age with standard deviation was 65.7±11.3 years; 65.7% of the patients were men. At 12 months, the primary outcome, TLF, occurred in 179 (6.7%), 151 (8.9%), 28 (2.9%) patients among the total, ISR, and de novo lesion populations, respectively. A history of hypertension, diabetes, acute coronary syndrome, previous coronary artery bypass graft, reduced left ventricular ejection fraction, B2C lesion and ISR lesion were independent predictors of 12 months TLF in the overall study population. This large multicenter DCB registry study revealed the favorable clinical outcome of DCB treatment in real-world practice in patient with ISR lesion as well as small de novo coronary lesion.